Literature DB >> 26468158

Pulmonary hypertension in polymyositis.

Han Wang1, Tao Liu2, Ying-ying Cai3, Lian Luo1, Meng Wang4, Mengmeng Yang1, Lin Cai5.   

Abstract

Pulmonary hypertension (PH) is relatively common in connective tissue diseases. However, few studies have focused on the pulmonary hypertension (PH) associated with polymyositis (PM). Our aim is to investigate the prevalence of PH and determine the associated factors for PH in patients with PM. Multicenter study of 61 patients with PM underwent evaluation including general information, physical examination, laboratory indictors, thoracic high-resolution CT (HRCT) imaging, and transthoracic echocardiography (TTE). TTE was performed to estimate the pulmonary arterial pressure. PH was defined as resting systolic pulmonary artery pressure (sPAP) ≥40 mmHg. PH was identified in ten patients (16.39 %) who had few cardiopulmonary symptoms. PM patients with PH had higher prevalence of interstitial lung disease (ILD) and pericardial effusion (PE) compared with patients without PH (18 vs. 11.5 %, p = 0.005; 11.5 vs. 9.8 %, p = 0.004; respectively). After controlling for age, gender, and potential factors, ILD and PE were independently associated with PH in patients with PM in multivariate analysis (OR = 8.193, 95 % CI 1.241-54.084, p = 0.029; OR = 8.265, 95 % CI 1.298-52.084, p = 0.025; respectively). Depending on TTE, the possible prevalence of PH was 16.39 % in patients with PM. Both ILD and PE may contribute to the development of PH in PM.

Entities:  

Keywords:  Echocardiography; Interstitial lung disease; Pericardial effusion; Polymyositis; Pulmonary hypertension

Mesh:

Year:  2015        PMID: 26468158     DOI: 10.1007/s10067-015-3095-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  29 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Pulmonary pathology in connective tissue disease.

Authors:  Anatoly Urisman; Kirk D Jones
Journal:  Semin Respir Crit Care Med       Date:  2014-03-25       Impact factor: 3.119

Review 3.  Pulmonary manifestations of polymyositis/dermatomyositis.

Authors:  Robert W Hallowell; Dana P Ascherman; Sonye K Danoff
Journal:  Semin Respir Crit Care Med       Date:  2014-03-25       Impact factor: 3.119

4.  Pericardial fluid profiles of pericardial effusion in systemic sclerosis patients.

Authors:  Patipat Kitchongcharoenying; Chingching Foocharoen; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Asian Pac J Allergy Immunol       Date:  2013-12       Impact factor: 2.310

Review 5.  Pulmonary pathology of the rheumatic diseases.

Authors:  Kevin O Leslie; Sylvain Trahan; James Gruden
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

Review 6.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

7.  Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy.

Authors:  Guillermo Ruiz-Irastorza; Maider Garmendia; Irama Villar; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Autoimmun Rev       Date:  2012-07-25       Impact factor: 9.754

8.  Pulmonary hypertension in polymyositis.

Authors:  T W Bunch; R G Tancredi; J T Lie
Journal:  Chest       Date:  1981-01       Impact factor: 9.410

9.  Asymptomatic pericardial effusion in patients with systemic lupus erythematosus.

Authors:  T Sugiura; Y Kumon; H Kataoka; Y Matsumura; H Takeuchi; Y L Doi
Journal:  Lupus       Date:  2009-02       Impact factor: 2.911

10.  Exercise limitation in patients with polymyositis.

Authors:  C A Hebert; T J Byrnes; B A Baethge; R E Wolf; G T Kinasewitz
Journal:  Chest       Date:  1990-08       Impact factor: 9.410

View more
  5 in total

1.  [Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement].

Authors:  L Luo; X Y Xing; Y S Xiao; K Y Chen; F Y Zhu; X W Zhang; Y H Li
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2021-12-18

Review 2.  The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.

Authors:  Wen Tian; Shirley Y Jiang; Xinguo Jiang; Rasa Tamosiuniene; Dongeon Kim; Torrey Guan; Siham Arsalane; Shravani Pasupneti; Norbert F Voelkel; Qizhi Tang; Mark R Nicolls
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 8.786

Review 3.  Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases.

Authors:  Nicola Ciancio; Mauro Pavone; Sebastiano Emanuele Torrisi; Ada Vancheri; Domenico Sambataro; Stefano Palmucci; Carlo Vancheri; Fabiano Di Marco; Gianluca Sambataro
Journal:  Multidiscip Respir Med       Date:  2019-05-15

4.  Clinical, Serological, and Genetic Characteristics of a Hungarian Myositis-Scleroderma Overlap Cohort.

Authors:  Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Tibor Béldi; Anett Vincze; Erika Zilahi; József Varga; Gabriella Szűcs; Katalin Dankó; Zoltán Griger
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

Review 5.  Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature.

Authors:  Sébastien Sanges; Cécile M Yelnik; Olivier Sitbon; Olivier Benveniste; Kuberaka Mariampillai; Mathilde Phillips-Houlbracq; Christophe Pison; Christophe Deligny; Jocelyn Inamo; Vincent Cottin; Luc Mouthon; David Launay; Marc Lambert; Pierre-Yves Hatron; Laurence Rottat; Marc Humbert; Eric Hachulla
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.